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Abstract
Nerve injury leads to sensitization mechanisms in the peripheral and central nervous system which involve transcriptional
and post-transcriptional modifications in sensory nerves. To assess protein regulations in the spinal cord after injury of the
sciatic nerve in the Spared Nerve Injury model (SNI) we performed a proteomic analysis using 2D-difference gel
electrophoresis (DIGE) technology. Among approximately 2300 protein spots separated on each gel we detected 55
significantly regulated proteins after SNI whereof 41 were successfully identified by MALDI-TOF MS. Out of the proteins
which were regulated in the DIGE analyses after SNI we focused on the carboxypeptidase A inhibitor latexin because
protease dysfunctions contribute to the development of neuropathic pain. Latexin protein expression was reduced after SNI
which could be confirmed by Western Blot analysis, quantitative RT-PCR and in-situ hybridisation. The decrease of latexin
was associated with an increase of the activity of carboxypeptidase A indicating that the balance between latexin and
carboxypeptidase A was impaired in the spinal cord after peripheral nerve injury due to a loss of latexin expression in spinal
cord neurons. This may contribute to the development of cold allodynia because normalization of neuronal latexin
expression in the spinal cord by AAV-mediated latexin transduction or administration of a small molecule carboxypeptidase
A inhibitor significantly reduced acetone-evoked nociceptive behavior after SNI. Our results show the usefulness of
proteomics as a screening tool to identify novel mechanisms of nerve injury evoked hypernociception and suggest that
carboxypeptidase A inhibition might be useful to reduce cold allodynia.
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Introduction
Injury to peripheral or central nerves may result in the
development of neuropathic pain [1]. Despite recent advances in
the understanding of the pathophysiology of this disease it is still
unclear why adaptive processes elicited by the injury allow for a
recovery of stability and normal neuronal excitability in the
majority of patients but fail in others [1–4]. Because injured
neurons adapt protein degradation and de novo synthesis to
prepare for the reorganization of signaling and synaptic functions,
proteome analyses from afflicted sites are likely to further unravel
the mechanisms and unfavorable regulations which challenge the
recovery of balance [5]. In the present study we used the Spared
Nerve Injury model of neuropathic pain [6] to screen for
proteomic manifestations in the spinal cord. Based on the
hypothesis that neuropathic pain may arise from a dys-balance
of activator/inhibitor or agonist/antagonist protein pairs we
focused on endogenous enzyme inhibitors. The analysis identified
latexin as a potential functionally relevant downregulated
candidate. Latexin is the only known endogenous inhibitor of
the C-terminal exopeptidase, carboxypeptidase A, which prefer-
entially cleaves off C-terminal hydrophobic L-amino acids that
have aromatic or branched side chains [7,8]. Carboxypeptidase A
isoforms contribute to the processing of opioid peptides,
neurotensin, corticotropin, angiotensin and other neuropeptides
[9–12]. It is therefore likely that a dys-balance between
carboxypeptidase A and its inhibitor, latexin may affect neuro-
peptide signaling in the spinal cord. Particularly, endogenous
opioid peptides are essential mediators in the endogenous defense
against pain and dysfunctions in endorphin or enkephalin
degradation may aggravate hyperexcitability of nociceptive
synapses [13]. Latexin is expressed in subsets of neurons of the
peripheral and central nervous system including cortical neurons
in the SII somatosensory cortex [14,15]. Recent studies suggest
that latexin deficient mice have a phenotype in some nociceptive
tests but not in others [15]. Based on our hypothesis and based on
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latexin in the spinal cord and dorsal root ganglia in the context of
neuropathic pain.
Methods
Animals and treatments
Ethics Statement. In all animal experiments the ethic
guidelines for investigations in conscious animals were obeyed
and the procedures were approved by the local Ethics Com-
mittee for Animal Research (Regierungspra ¨sidium Darmstadt,
Germany).
For the proteomic analysis male Sprague Dawley rats (Charles
River, Sulzbach, Germany) weighing 260–300 g were used. They
were housed in groups of five in standard cages and maintained in
climate- and light-controlled rooms (2260.5uC, 12/12 h dark/
light cycle) with free access to food and water. To assess the effect
of latexin transduction or carboxypeptidase inhibitor on the
neuropathic pain behavior we used C57BL/6 mice to reduce the
amount of viruses and drug which would have been needed to
modulate latexin or carboxypeptidase activity in the spinal cord of
rats, respectively.
Nerve injury
The spared nerve injury (SNI) model was used as described
previously [6,16]. Briefly, animals were anesthetized with
isoflurane, and the tibial and common peroneal branches of the
sciatic nerve were ligated and sectioned distally, whereas the sural
nerve was left intact. For sham surgery the sciatic nerve was
exposed but not touched. Sham operated and naı ¨ve animals were
used as controls. Animals were sacrificed at the indicated time
points after surgery and the L4/L5 DRGs (ipsi- and contralateral)
and the lumbar spinal cord (L4/5) were dissected for further
analysis. The spinal cord was then further prepared to separate the
ipsi- and contralateral dorsal and ventral horns. Therefore, lumbar
spinal cords were placed under a microscope and the sections were
prepared by a micro scalpel. For proteomic studies nine animals
were analyzed in each group. For RNA analysis and in situ
hybridisation three and six animals, respectively, have been used
in each group.
Preparation of protein extracts
Protein extracts from DRGs and lumbar dorsal horn tissue were
prepared using a lysis buffer containing 8 M urea, 4% CHAPS,
30 mM Tris, 1 mM PMSF pH 8.5. After removal of cellular
debris extracts were ultracentrifuged at 40,000 rpm for 1 h (4uC)
and the supernatant was stored at 280uC until analysis. Protein
concentrations were determined by the Bradford protein assay.
2-D DIGE Analysis
For DIGE analysis 9 rats/group have been used and 3 gels were
run/experiment. Individual protein samples (50 mg) were mini-
mally labelled with the fluorescent dyes Cy2 (SNI dorsal horn
ipsilateral, 7 days after surgery), Cy3 (internal standard), or Cy5
(sham operated dorsal horn ipsilateral, 7 days after surgery)
(400 pmol dye each, GE Healthcare) according to manufacturer’s
instructions. As internal standard a protein mixture consisting of
control and SNI samples was used. Fluorescence labelling was
carried out for 30 min in the dark, and the reaction was stopped
by the addition of 1 ml 10 mM L-lysine for 10 min on ice in the
dark. Labelled samples were applied to rehydrated 18 cm non-
linear pH 3–10 IPG strips (Immobiline DryStrips, GE Healthcare)
by anodic cup loading and IEF was performed for a total of
56000 Vh on an IPGphor system (GE Healthcare). After IEF, the
strips were equilibrated at room temperature for 15 min in
50 mM Tris-HCl, 6 M urea, 30% (v/v) glycerol, 2% SDS (w/v)
and 0.002% (w/v) bromphenol blue containing 1% (w/v) DTT
and then, for 15 min in the same buffer without DTT, but with
the addition of 4.8% (w/v) iodoacetamide. Proteins were further
separated according to their molecular weight on SDS-PAGE
(12.5%) using an Ettan DALTsix system (GE Healthcare).
Following electrophoresis, gels were fixed and then scanned at
appropriate wavelengths for Cy2, Cy3, and Cy5 fluorescence using
a Typhoon 9400 (GE Healthcare) scanner. Protein expression was
quantified using DeCyder Batch Processor and Biological
Variation Analysis (BVA) software V5.02.
In-gel digestion and MALDI-TOF-MS
Protein spots showing an SNI-evoked change of expression of at
least 40% were picked using an Ettan Spot Picker. Cut out gel
pieces were subjected to in-gel digestion protocols [17] which were
adapted for use on a Microlab Star digestion robot (Bonaduz,
Switzerland) [18]. Briefly, samples were reduced, alkylated and
subsequently digested using bovine trypsin (Roche, Mannheim,
Germany). The digestion mixture was dissolved in 5 ml of 50%
acetonitrile/1% trifluoroacetic acid (TFA). The samples (0.5 ml)
and 0.5 ml of matrix (2 mg/ml 1-cyano-4- hydroxycinnamic acid
in 50% acetonitrile/0.5% TFA) were consecutively spotted and
dried in ambient air. MALDI-TOF mass spectra were recorded on
an Ultraflex TOF/TOF (Bruker Daltonics, Bremen) using a
nitrogen laser (l=337 nm, repetition rate=25 Hz) for desorption
and ionisation with an acquisition mass range from 700 to
5000 m/z. The low mass gate was set to 650 m/z. Spectra were
externally calibrated with Sequazyme Peptide Mass Standards Kit
(Applied Biosystems, Darmstadt). Between 1000 and 2000 single
scans were accumulated for each mass spectrum. Monoisotopic
peaks were labeled using flex analysis V2.2. Proteins were
identified using MASCOT 2.0 (Matrixscience) installed on a local
server using the current National Centre for Biotechnology
Information (NCBI) database (NCBInr 20050721 (2693904
sequences; 923764693 residues, Timestamp: 25 Jul 2005 at
14:15:12 GMT) without species restriction. For peptide-mass
fingerprinting, the most intense peaks were submitted using a
search with the following parameters: Enzyme: Trypsin; Fixed
modification: Carbamidomethyl (C), variable modifications: oxi-
dation (M), mass values: monoisotopic, protein mass: unrestricted,
peptide mass tolerance: 50 ppm, peptide charge state: 1+, Max
missed cleavages:1). Proteins with a score of 77 or higher were
considered significant (p,0.05).
Western Blot analysis
Protein lysates (30 mg) were separated by 12% SDS–PAGE.
Proteins were then transferred onto nitrocellulose membranes by
wet blotting. To confirm equal loading all blots were stained with
Ponceau red solution. Membranes were blocked for 60 minutes at
room temperature in Odyssey blocking reagent (LI-COR
Biosciences) diluted 1:2 in PBS. Then the blots were incubated
overnight at 4uC with primary antibody against carboxypeptidase
A (37 kDa) (1:400, Biogenesis, Poole, UK) or latexin (28 kDa)
(1:100, Santa Cruz, Heidelberg, Germany) in blocking buffer.
After washing three times with 0.3% Tween 20 in PBS, the blots
were incubated for 60 min with an IRDye800- or IRDye700-
conjugated secondary antibody (1:10000 in blocking buffer). After
rinsing in 0.3% Tween 20 in PBS, protein-antibody complexes
were detected with the Odyssey Infrared Imaging System (Licor,
Bad Homburg, Germany). ERK-2 (42 kDa) (1:2500, Santa Cruz,
Heidelberg, Germany) was used as loading control.
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CPA activity in preparations of the lumbar spinal cord has been
determined as described previously [19–21] with slight modifica-
tions. As CPA substrate we used N-Acetyl-L-phenylalanyl-L-3-
thiaphenylalanine (Peptides International, Louisville, USA) which
is hydrolysed by active CPA. The released thiophenole reacts to a
yellow dye by addition of Ellmans reagent. The absorbance of the
product was measured photometrically at 410 nm (Spectrafluor
Plus, Tecan, Crailsheim, Germany).
Quantitative RT-PCR
Total RNA was extracted from tissues and cells as described
previously [22]. mRNA expression was analysed using a One-step
RT-PCR Kit (Qiagen, Hilden, Germany). Primers used for RT-
PCR analysis are shown in Table 1.
Reverse transcription reaction was performed with specific
primers at 50uC for 30 min. PCR amplification was started by
enzyme activation at 95uC for 10 min. The samples were then
denatured at 95uC for 1 min, annealed at 58uC 1 min and
extended at 72uC for 1 min in 35 repetitive cycles. After a final
extension at 72uC for 10 min the PCR was stopped and the
samples were separated by 1% agarose gel electrophoresis. The
amplified cDNA bands were detected by ethidium bromide
staining.
For Taqman analysis cDNA synthesis was performed with
random hexamers using the Superscript III kit (Invitrogen GmbH,
Karlsruhe, Germany). The expression levels of latexin were
determined by SYBR Green labeling (Abgene Limited, Epsom,
United Kingdom) with an ABI Prism 7500 Sequence Detection
System (Applied Biosystems, Austin, USA). The variability of
mRNA input was normalized to the amount of 18SRNA.
In situ hybridization
A cDNA was reverse transcribed from rat spinal cord mRNA
with random primers. The primers 59-AAATCCCACCCACC-
CACTAC-39 and 59-ATTGTGGGTGCCACAGAACT-39 were
used to synthesize a fragment corresponding to nucleotides 8–616
of latexin mRNA (NM_031655) by PCR. Agarose gel electropho-
resis presented a single band with the expected size. The fragment
was cloned into the pCR4-TOPO plasmid vector (Invitrogen,
Karlsruhe, Germany) and transformed into E. coli. Isolated
plasmid was linearized with NotI and PmeI and digoxigenin-labeled
sense and antisense probes were produced by reverse transcription
using T3 or T7 RNA polymerases, respectively.
Lumbar spinal cord as well as dorsal root ganglia (DRG, L3–L5)
were dissected and immediately frozen in tissue freezing medium
on dry ice. Cryostat sections were cut at a thickness of 16 mm and
fixed in 4% paraformaldehyde in 0.1 M PBS (pH 7.4) for 10 min.
After rinsing in PBS, samples were acetylated with acetic
anhydride in 0.1 M triethanolamine for 10 min, pre-hybridized
in hybridization buffer (50% formamide, 56SSC (diluted from a
206SSC stock solution: 3 M NaCL, 0.3 M Na-Citrat, pH 7.0),
56Denhardt’s solution, 500 mg/ml herring sperm DNA, 250 mg/
ml yeast tRNA) at 70uC for 2 h, and incubated with latexin sense
or antisense probes in hybridization buffer (300 ng/ml) at 70uC
overnight. After hybridization, the slides were washed twice in
0.26 SSC and TBS (0.1 M Tris-HCl, 0.15 M NaCl, pH 7.5) at
70uC, incubated for 1 h in blocking buffer (0.12 M maleic acid,
Table 1. Primers used for RT-PCR analysis.
Gene
Accession
number Abbrevation
Amplification
product (bp) Primer sequence
Annexin A4 NM_024155 Anxa4 248 FW 59-GCAGAGATTGACATGCTGGA-39
RV 59-CTGGAGGCGTTTTAATTGGA -39
Latexin NM_031655 Lxn 420 FW 59-GGAAGAGGCCACAAGTACCA-39
RV 59-GTCGTGGAGTAGGACGGTGT -39
Peptidylprolyl isomerase A NM_017101 Ppia 248 FW 59-AGCACTGGGGAGAAAGGATT -39
RV 59- AGCCACTCAGTCTTGGCAGT-39
Prohibitin M61219 Phb 187 FW 59- GGCAGCCTGAGTAGACCTTG-39
RV 59- TCACGGTTAAGAGGGAATGG-3
Cytochrome c oxidase XM_578078 CCO 235 FW 59- GCTGGCAGAACTACCTGGAC-39
RV 59- GAGGTCCCCCTTTTCTATCG-39
Ubiquitin carboxy-terminal hydrolase D10699 UCH 189 FW 59- CTAGGGCTGGAGGAGGAGAT-39
RV 59-CCCAATGGTACCACAGGAGT-39
Pyruvate dehydrogenase U10357 PD 149 FW 59- AGGAAGTCAATGCCACCAAC-39
RV 59- TTTTGATGGGAGGGAGAGTG-3
Serine/threonine-specific protein kinase AF068261 STK 200 FW 59- CAAGAAGGTCAGGCGAGTTC-39
RV 59-ACTGTATTTGCTCGGGGATG-39
Myelin basic protein K00512 MBP 176 FW 59- GCACCCTGACTGGCTAAAAC-39
RV 59- CTCGCCGTGAAAAGAAAGTC-39
Glutathione-S-transferase, mu 5 NM_172038 GSTM5 210 FW 59- GCACAACATGTGTGGTGACA -39
RV 59- AGCTTTTCTCCTGCAAACCA -39
NADH dehydrogenase (ubiquinone) Fe-S protein 3 XM_215776 NADH DH 243 FW 59- AGCAGTGGATGTCCCAACTC-39
RV 59- TGTCCCTCGAAGCCATAATC-39
Phosphoglycerate mutase S63233 PGM 198 FW 59- CTCAGGGCAAGGTGAAGAAG-3
RV 59- GGTGCCGGGGATAAAATACT-39
Beta-actin NM_031144 Actb 300 FW 59-CAGCGGAACCGCTCATTGATGG-39,
RV 59-TCACCCACACTGTGCCCAACGA-39
doi:10.1371/journal.pone.0019270.t001
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Mannheim, Germany) followed by incubation of alkaline phos-
phatase-conjugated anti-digoxigenin antibody (1:1000, Roche
Diagnostics) in blocking buffer at 4uC overnight. Sections were
then washed in TBS and equilibrated in alkaline buffer (0.1 M
Tris-HCl, 0.1 M NaCl, 0.05 M MgCl2, pH 9.5, 2 mM levami-
sole). A colorimetric reaction using BM Purple AP substrate
(Roche Diagnostics) was performed at room temperature for 1–
2 h. Images were obtained using an Eclipse E600 microscope
equipped with a Kappa DX 20 H camera and Kappa ImageBase
software. BM Purple-stained latexin mRNA was visualized using
brightfield illumination.
Preparation of latexin-containing adenovirus
Full length latexin cDNA was obtained by using total RNA from
mouse spinal cord using specific mouse latexin primers, carrying
BamHI and NheI restriction sites (RV with BamHI restriction site
(underlined): 59-CGT CTT GGA TCC TCC GCC TGC CCT
TC-39; FW with NheI restriction site (underlined): 59-TCT CCG
CTA GCA TGG AAA TCC CAC CCA CCC AC-39) (Biospring,
Frankfurt, Germany). The 665 bp PCR product encoding latexin
was inserted into the multiple cloning site of a neuron-specific
adenovirus associated vector (AAV2) in front of green fluorescence
protein (EGFP) as a fusion product. In this vector latexin-EGFP
expression is controlled by the human synapsin 1 promoter to
ensure neuron specificity [23,24]. The vector was amplified in
E.coli DH5a and selected positive recombinants were confirmed by
sequencing analysis by AGOWA, Berlin, Germany. Recombinant
adenoviruses were produced in 293A HEK cells (Microbix,
Canada) by transient co-transduction of AAV2 with two helper
plasmids containing rep2 and caps1 genes and adenovirus viral-
associated (VA) RNA polymerase I and II genes. A standard
calcium-phosphate method was used for transduction and the cells
were maintained in Dulbecco’s modified Eagle’s medium
(Invitrogen) supplemented with 10% fetal bovine serum (Hyclone),
1% glutamate, and 1 mM sodium pyruvate (Invitrogen) in a 37uC
incubator with 5% CO2. Six hours after transduction, the medium
was replaced by fresh pre-warmed DMEM culture medium
containing 2% FCS. Two-three days post-transduction, the
efficiency of viral infection was determined by EGFP fluorescence
microscopy (Zeiss Axio-Imager, Zeiss, Germany) and FACS
analysis. Cells were lysed by three freezing/thawing cycles and
adenovirus stocks were stored at 280uC till use. Latexin
transduction of human neuroblastoma cell cultures (SH-SY5Y)
was analysed by RT PCR 3 days after transduction with AAV2-
Syn-Latexin-EGFP.
Intrathecal injection of adenovirus in mice
Mice were anesthetized with a mixture of fentanyl (2.1 mg/kg)/
midazolam (21 mg/kg) to minimize respiratory thoracic move-
ments during surgery. After blunt removal of back muscles and
ligaments we performed a minimal hemi-laminectomy above the
L4–5 lumbar spinal cord. Using a Nanoliter Injector (World
Precision Instruments (WPI), Berlin, Germany) equipped with a
glass capillary we injected a total of 372 nl of AAV2-hSyn-
Latexin-EGFP solution (10
11–10
12 VP/ml) carrying the latexin
cDNA or empty AAV2 carrying an identical expression cassette
without transgene (control) into the ventral and dorsal horns at 3
adjacent sites of the L4–5 lumbar spinal cord ipsilateral to the
nerve lesion. The injection was performed 7 days before SNI
surgery. Nociceptive behavior was assessed before virus injection
and 7 days after virus injection before nerve injury to determine
the baseline and then at days 3, 7, 14, 21 and 28 after nerve injury.
13–14 animals were used in each group.
Oral treatment with carboxypeptidase inhibitor
To inhibit carboxypeptidase activity in mice we used the small
molecule DL-benzylsuccinic acid (Sigma) which has been
described as potent carboxypeptidase inhibitor [25]. The drug
was dissolved at a concentration of 1 mg/ml in tap H2O and
then administered at a dose of 200 mg/kg body weight/day with
the drinking water. Treatment started 3 days before SNI
surgery. Baselines for nociceptive behavior were determined
before the first drug administration and then at day 3 after drug
treatment before surgery. The nociceptive behavior after SNI
was assessed on days 3, 7 and 14. Six mice have been used in
each group.
Analysis of nociception
Behavioral tests were performed in a silent room with constant
temperature (21–23uC) during daylight after adaptation of the
animals to the test cages with a metal grid bottom. The
experimenter was blinded to treatment of the animals. All animals
have been used to assess both parameters. The experiments were
performed in the same order in each measurement.
Mechanical hyperalgesia. Paw withdrawal latency to
mechanical stimulation was assessed with an automated testing
device consisting of a steel rod that was pushed against the plantar
surface of the paw with increasing force until the paw was
withdrawn (Dynamic Plantar Aesthesiometer, Ugo Basile, Varese,
Italy). The maximum force was set at 5 g and the ramp speed was
0.5 g/s.
Cold allodynia. To assess cold allodynia in the SNI-model a
drop of acetone was applied with help of a 1 ml syringe onto the
plantar side of the hindpaw ipsilateral to the nerve lesion. The time
the mice spent lifting, shaking or licking the acetone treated paw
was recorded with a stop watch during an observation period of
2 min starting right after acetone application.
Immunofluorescence
Mice were intracardially perfused with 0.9% saline followed by
4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS,
pH 7.4) under deep ketamine/xylazine anesthesia. The lumbar
spinal cord was dissected, post-fixed in the same fixative for 2.5 h
and cryoprotected in 30% sucrose overnight. Tissues were frozen
in tissue freezing medium on dry ice and cryostat-sectioned at a
thickness of 14 mm. Slices were permeabilized for 15 min with
PBS containing 0.1% Triton-X 100. The sections were then
blocked in 3% BSA in PBS for 1 h to reduce nonspecific binding
and incubated overnight at 4uC with the primary antibody against
neuronal nuclear protein (NeuN) to confirm neuron-specific
infection with the AAV2-hSyn-Latexin-EGFP. Species specific
secondary antibody labelled with Cy3 was used for microscopic
detection. Adenovirus infection was detected by the EGFP signal.
Slides were mounted with SlowFade Light Antifade mounting
media according to manufacturer’s protocol (Molecular Probes,
Leiden, The Netherlands) and then analysed using a Zeiss
AxioImager fluorescence microscope.
Data analysis and statistics
Statistical evaluation was done with SPSS 12.0 for Windows.
Data are presented as means 6 SEM. For comparison of
Western Blot and TAqman PCR analysis we applied unpaired
Students t-test. For statistical comparisons of behavioral data we
submitted time course data to an analysis of variance (ANOVA)
for repeated measurements and calculated the area under the
time curve (AUC) employing the linear trapezoidal rule. AUCs
were subsequently compared with unpaired Student’s t-tests
Latexin and Neuropathic Pain
PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e19270Figure 1. DIGE analysis. (A) Representative 2D-gels of the lumbar spinal cord of sham-operated rats, 7 days after nerve injury and internal control
(Sham/SNI 1:1). (B) Overlay of the 3 images indicating regulated protein spots.
doi:10.1371/journal.pone.0019270.g001
Table 2. mRNA expression in the spinal cord and the DRGs.
Spinal Cord DRGs
DH contra [%] ± SEM DH ipsi [%] ± SEM DRG contra [%] ± SEM DRG ipsi [%] ± SEM
Prohibitin 100.0±1.78 60.5±2.56*** 100.0±3.27 71.3±4.61**
Pyruvate dehydrogenase 100.0±2.39 63.7±7.48** 100.0±2.09 82.8±4.01 *
Annexin A4 100.0±1.86 83.1±2.95** 100.061.50 78.2610.14
Latexin 100.0±1.20 79.7±7.20* 100.063.71 87.264.43
Ubiquitin carboxy-terminal hydrolase 100.0±15.46 43.2±5.51* 100.062.94 96.968.19
Phosphoglycerate mutase 100.0±1.91 106.6±1.82* 100.064.34 94.563.91
Cytochrome c oxidase 100.063.85 114.7610.84 100.0±1.19 91.9±1.87*
Glutathione-S-transferase. Mu 5 100.068.26 102.866.92 100.0±2.90 79.3±5.18*
Myelin basic protein 100.060.52 103.264.98 100.066.78 97.161.31
NADH dehydrogenase (ubiquinone) Fe-S protein 3 100.061.92 109.668.86 100.065.32 87.769.77
Serine/threonine-specific protein kinase 100.061.02 107.564.39 100.068.65 90.0610.40
Peptidylprolyl isomerase A 100.063.92 92.362.05 100.061.75 102.962.86
mRNA expression in the ipsi- and contralateral dorsal horn (DH) of the spinal cord and the DRGs, respectively. Significantly regulated mRNA levels are indicated by bold
numbers (*P,0.05, **P,0.01; ***P,0.001).
doi:10.1371/journal.pone.0019270.t002
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ap r o b a b i l i t yv a l u eP ,0.05 was considered as statistically
significant.
Results
Differential protein expression following spared nerve
injury
The proteome of spinal cord lumbar dorsal horn samples
from SNI and sham operated rats was analyzed by 2D-DIGE.
An average of 2300 protein spots/gel distributed in a range
of pI 4.0–9.0 and MW between 20–150 kD were detected.
Differential expression was considered at .40% difference of
the spot intensity. We found 55 significantly regulated proteins
from which one spot was up- and 54 were down-regulated
after SNI. Fig. 1A shows representative 2D-gels of dorsal horn
protein extracts of sham-operated rats, 7 days after SNI and
the internal control (Sham/SNI 1:1), respectively. Proteins that
were at least 40% regulated 7 days after nerve injury are
indicated in the overlay image of the 3 gels (Fig. 1B). For
comparison, a regulation of only 20% spot intensity revealed 91
down-regulated and 18 up-regulated proteins (data not shown).
The 55 regulated spots were picked and identified by peptide-
mass fingerprinting using MALDI-TOF-MS with subsequent
Mascot database search. With this procedure we identified 41
proteins (Table S1) which are mostly involved in energy
metabolism, cellular structure, signal transduction and DNA
binding.
Analysis of gene expression of altered proteins by RT-PCR
Gene expression analysis of 12 selected proteins which are
potentially involved in nociceptive transmission was performed
by RT-PCR to further assess the regulation at the transcrip-
tional level. In concordance with the protein level, we found that
mRNAs were down regulated for prohibitin (PHB), Annexin A4
(Anxa4), pyruvate dehydrogenase (PD), ubiquitin carboxyterm-
inal hydrolase (UCH), and latexin (Lxn) 7 days after nerve
injury. Interestingly, phosphoglycerate mutase (PGM) mRNA
was significantly upregulated while protein levels were reduced
in 2D-PAGE. The mRNA of peptidylprolyl isomerase A (Ppia),
glutathione S-transferase, mu 5 (GSTM5), myelin basic protein
(MBP), serine/threonine specific kinase (STK), NADH dehy-
drogenase (NADH DH) and cytochrome C oxidase (CCO)
showed no significant differences between the ipsi- and the
contralateral side at the transcriptional level indicating that
the observed down regulation in the DIGE-analysis was
due to translational or post-translational modifications or
changes of the subcellular localization. We additionally deter-
mined mRNA levels of these candidate regulated proteins in
the L4/5 DRGs using the same primers. The results were
similar to the spinal cord: PHB, PD, GSTM5, and CCO were
significantly down regulated 7 d after SNI while Anxa4, Lxn,
NADH DH, STK, PGM, UCH MBP and Ppia remained
unaltered (Table 2).
Regulation and localisation of the carboxypeptidase A
inhibitor latexin
Since latexin has been described for its expression in pain-
relevant tissues in the peripheral and central nervous system
[7,26,27] and has been implicated in pain-signalling pathways
[14,15] we focused on the functional analysis of latexin. Western
Blot analysis revealed a significant downregulation of latexin
protein levels in the dorsal horn of the spinal cord ipsilateral to the
nerve lesion in comparison to sham operated control rats 7 days
after surgery thus confirming the data obtained from the DIGE
analysis (Figure 2A). Quantitative Taqman RT-PCR showed a
significant decrease in latexin mRNA after SNI in the spinal cord
(Figure 2B). In situ hybridization demonstrated latexin mRNA
expression in dorsal horn and motor neurons in the spinal cord
and in sensory neurons in the DRGs (Figure 2C and 2D). Seven
days after SNI surgery we observed a decrease in latexin mRNA in
the spinal dorsal and ventral horns ipsilateral to the nerve lesion
(Figure 2C). The mRNA expression of latexin in the DRGs did not
change after SNI (Figure 2D) and Western Blot analysis also did
not reveal differences in latexin protein levels in the DRGs
(Figure 2E).
Carboxypeptidase expression and activity after SNI
Since latexin is an endogenous inhibitor of carboxypeptidase A
in mammals a modulation of latexin expression may affect
carboxypeptidase activity. Western Blot analysis showed no
differences in the protein levels of carboxypeptidase A in the
ipsilateral dorsal horn of the spinal cord after SNI (Figure 3A).
However, activity assays revealed an increase of CPA-activity after
SNI which is in line with the decreased expression of its inhibitor
latexin (Figure 3B).
Neuropathic pain after adenovirus-mediated prevention
of latexin downregulation
We next assessed whether the nerve injury-evoked latexin loss in
the spinal cord promoted the development of neuropathic pain.
To prevent the loss of latexin we used an AAV-mediated
transduction approach to enhance and restore latexin expression
in the spinal cord ipsilateral to the nerve lesion. We used mice to
facilitate surgery and transduction in these experiments. The
downregulation of latexin after SNI was equivalent in mice and
rats (data not shown). Recombinant rAAV2 (rAAV2-hSyn-latexin-
EGFP) mediated enhancement of latexin expression was con-
firmed in human neuroblastoma cells (SH-SY5Y) (Figure 4A). In
vivo, we assessed successful latexin transduction in the spinal cord
by microscopic analysis of EGFP signals. Co-immunostainings
with marker antibodies for neurons confirmed the intended
neuron specificity (Figure 4B). We found positive neurons in an
area of few millimetres surrounding the injection sites.
In experiments where we prevented the SNI evoked latexin
decrease by rAAV2-mediated neuron-specific latexin transduction
in the ipsilateral spinal cord carboxypeptidase A activity
decreased. This confirmed the reciprocal relationship between
latexin expression and carboxypeptidase A activity. The neuro-
Figure 2. Latexin regulation in the spinal cord and the dorsal root ganglia (DRGs). (A) Western Blot showing latexin protein regulation in
the ipsilateral dorsal horn of the spinal cord in rats three (P=0.25) and seven days after nerve injury in the Spared Nerve Injury model (SNI). The
diagram depicts the result from the densitometric analysis of the blots (n=3 animals/group) (B) mRNA expression in the ipsi- and contralateral spinal
cord after SNI as investigated by quantitative RT-PCR (Taqman) (C) Latexin mRNA in the dorsal and ventral spinal cord ipsi- and contralateral to the
nerve lesion analysed by in situ hybridisation. (D) In situ hybridisation of latexin in ipsi- and contralateral DRGs in SNI- and sham-operated rats. The
diagram shows the mean counts of latexin-positive neurons in the respective DRGs. (E) Western Blot showing latexin protein regulation in the ipsi-
and contralateral DRGs in SNI-operated rats. The diagram depicts the result from the densitometric analysis of the blots. Data are shown as mean 6
SEM,
*P,0.05, Scale bar: 100 mm.
doi:10.1371/journal.pone.0019270.g002
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monitoring cold allodynia and mechanical hyperalgesia. Mechan-
ical nociception was identical in mice tranduced with rAAV2-
hSyn-latexin-EGFP or control virus which contained an identical
expression cassette without transgene. However, cold allodynia
was significantly reduced after treatment with rAAV2-hSyn-
latexin-EGFP (repeated measure ANOVA p,0.001; t-test of
AUC[0–28d] p,0.05) (Figure 5 A–C) indicating that normalization
of latexin expression was able to prevent the development of cold-
induced hypernociception.
Mice treated orally with the carboxypeptidase inhibitor D,L-
benzylsuccinic acid showed a significant reduction in carboxypep-
tidase activity in the spinal cord. This was associated with a
significant reduction of cold allodynia but not mechanical
hyperalgesia. Hence, the effects of CPA inhibition with a small
molecule inhibitor resembled those of latexin transduction
(Figure 5 D–F). The result suggests that carboxypeptidase A
contributes to the development of cold allodynia, but not
mechanical hyperalgesia.
Discussion
Neuropathic pain is characterized by hypersensitivity in the
peripheral and central nervous system and urgently requires
specific and effective treatment. This is often constricted since
currently available drugs are ineffective or associated with severe
dose-limiting side effects. A better knowledge of the molecular
mechanisms of neuropathic pain which involve a number of
changes in the protein expression pattern in neuronal tissues might
facilitate the development of novel therapies. In the present study,
proteomics revealed latexin as a candidate protein involved in
nerve injury evoked hypernociception. We found abundant
expression of latexin in dorsal and ventral horn neurons in the
spinal cord where it functions as carboxypeptidase inhibitor. Its
strong downregulation after nerve injury resulted in increased
CPA activity. Counter-regulation of this process by AAV-
mediated latexin cDNA delivery or administration of a carboxy-
peptidase inhibitor reduced neuropathic pain-like behavior
suggesting that the latexin/carboxypeptidase A system may
contribute to the manifestation of cold allodynia in the SNI model.
The proteomic 2D-DIGE approach used in the present study
revealed the regulation of several proteins in the dorsal horn of
the spinal cord following a peripheral lesion of the peroneal and
tibial branches of the sciatic nerve in the spared nerve injury
model of neuropathic pain. Previous proteomic studies from
spinal cord or DRG tissue found modifications of various proteins
in neuropathic pain models (reviewed in [5]). A comparison of
the results from different studies shows partly overlapping but
mostly inconsistent protein modulations which might be due to
the use of different nerve injury models, different animal strains
or analysis of different neuronal tissues, and may also result from
technical differences such as protein extraction protocols,
coverage of the isoelectric focussing and molecular weight range,
gel development and mass spectrometry detection. The Spared
Nerve Injury model of neuropathic pain has not yet been
investigated in terms of proteomics but was previously analysed
for changes in mRNA expression in microarray studies [28]. In
the present study we identified modifications of proteins involved
in energy metabolism, maintenance of cellular structure and
adherence, signal transduction and DNA binding. Some of these
proteins were identified previously in proteomic studies with
other nerve injury models (shown in Table S1), indicating that
Figure 3. Carboxypeptidase A (CPA) expression and activity in the spinal cord. (A) Western Blot analysis of CPA protein levels and (B) CPA
activity in the ipsilateral spinal cord of sham and SNI operated animals. Data are shown as mean 6 SEM, *P,0.05 (n=5–6/group). For better
comparison, controls are set as 100%.
doi:10.1371/journal.pone.0019270.g003
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response to nerve injury and/or abundant expression and strong
regulation of these proteins upon nerve injury, such as the
mitochondrial protein prohibitin or the ubiquitin hydrolase L1.
However, the bulk of the detected proteins were not found in
previous proteomic analyses suggesting that they may be
specifically regulated in the SNI model. A comparison between
mRNA and protein levels of the respective proteins revealed that
a number of regulations occur at the transcriptional level while
several others appear to be translational or posttranslational
modifications. Changes of protein stability and degradation may
represent important immediate but also long lasting adaptive
responses to the nerve injury. Because proteases determine
longevity of proteins we focused on the protease inhibitor latexin
as a candidate protein for further functional analysis. Recent
reports showed that proteases of the metalloproteinase group [29]
as well as some cathepsins [30] play important roles in the
activation of glial cells in the spinal cord after nerve injury and
the development of neuropathic pain. We found abundant latexin
mRNA in dorsal and ventral horn neurons of the spinal cord and
a dramatically diminished neuronal latexin expression on the side
ipsilateral to the peripheral sciatic nerve lesion. Latexin is
expressed in small-diameter peptidergic CGRP and substance P
positive neurons in dorsal root ganglia [14] i.e. a proportion of
nociceptive neurons. Previously, latexin knockout mice displayed
an increased tail flick latency as compared to wild type animals
upon noxious heat stimulation [15] suggesting that the here
observed dramatic loss of latexin expression after nerve injury in
spinal cord neurons may impact on the manifestation of
neuropathic pain. Latexin is the only known endogenous
carboxypeptidase A inhibitor in mammals [7] and in this regard
it may be important to balance protein degradation in injured
neurons [31]. We expected that the nerve injury evoked
disappearance of latexin in spinal cord neurons should increase
carboxypeptidase A activity and possibly enhance protein
breakdown of carboxypeptidase substrate proteins or peptides.
Among them are the endogenous opiod leu-enkephalin [32] and
endothelin-1 [33] which may impact on the endogenous ability of
nociceptive control [34,35]. Increased cleavage particularly of
endogenous opioid peptides might contribute to the development
of neuropathic pain. The reciprocal relationship between latexin
expression and carboxypeptidase A activity was confirmed in our
study. Furthermore, we were able to prevent both the latexin
disappearance and CPA enhancement with a rAAV2-mediated
restoration of latexin expression specifically in neurons. Latexin
restoration and inhibition of carboxypeptidase was associated
with attenuated neuropathic cold pain-like behavior. We did not
observe differences in heat pain sensitivity (not shown) which had
been reported in latexin deficient mice [15]. Latexin knockout
mice had shown prolonged paw withdrawal latency times upon
acute heat stimulation in the Hot Plate test, indicating a reduced
sensitivity to heat pain [15]. It is conceivable that CPA may have
opposite effects in acute and nerve injury evoked nociception.
However so far, exaggerated protease activity has been mainly
observed in the context of chronic enhancement of inflammatory
pain or nerve injury-evoked nociception. The interpretation of
nociceptive behavior in latexin deficient mice is hampered by the
general knockout approach because latexin deficiency may
Figure 4. AAV-mediated overexpression of latexin. (A) RT PCR of latexin in SH-SY5Y neuroblastoma cells (naive or transduced with adenovirus
with and without latexin) and (B) Spinal cord slices of mice 7 days after injection of AAV2 latexin virus. Upper panel: EGFP staining, middle; NeuN
immunofluorescence, Lower panel Merged; Scale bar 10 mm.
doi:10.1371/journal.pone.0019270.g004
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neurons occurs early during embryogenesis at E11 and plays a
role in the regional specification and morphogenesis of the
forebrain [36]. In line with our observations in adult rodents
sectioning of the sciatic nerve in P2 neonates also resulted in a
dramatic reduction of latexin immunoreactivity in the spinal cord
[14] indicating that this adaptation was fully functioning at birth.
Prevention of the consequent CPA enhancement might be useful
to attenuate nerve injury evoked nociceptive hypersensitivity,
particularly cold allodynia. We do not know why carboxypepti-
dase inhibition was specifically important for cold allodynia but
not mechanical hyperalgesia. It might be expected that latexin
and carboxypeptidase are specifically important for cold-respon-
sive nociceptive neurons to control protein cleavage. Latexin
expression in the DRGs however, was not restricted to TRPA1
positive neurons. Nonetheless, subsets of specific neurons may be
particularly sensitive to latexin-CPA dys-balances owing to
cleavage of a CPA-subtype specific substrate [37]. So far, 6
CPA subtypes have been characterized which may be differen-
tially expressed in subsets of neurons. From anatomical studies of
the cortex it had been previously inferred that an area- and
lamina-specific distribution of latexin-expressing neuronal sub-
populations was important for the functional specialization of the
cortical areas [38]. Such latexin-dependent specialization might
also occur in the spinal cord. In summary, our results show that it
is feasible to restore protein expression by AAV-mediated gene
delivery in the spinal cord and thereby restore the balance
between protease and endogenous inhibitor to reduce nerve
injury evoked cold allodynia. Specific small molecule CPA
inhibitors might be useful to reduce cold pain.
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Figure 5. Nociceptive behavior after CPA-inhibition either by AAV-mediated latexin rescue or the CPA inhibitor D, L-benzylsuccinic
acid. (A) CPA activity in the spinal cord of SNI treated mice injected either with adenoassociated virus backbone (empty AAV2) or AAV2-latexin.
(n=5–6/group). CPA activity of controls is set at 100%. (B) Mechanical hyperalgesia assessed with a dynamic von Frey apparatus and (C) cold
allodynia assessed in the acetone test in AAV2 treated mice. (n=13–14 animals in each group), m empty AAV2,N AAV2 latexin. (D) CPA activity in the
spinal cord of SNI treated mice with or without oral administration of the CPA inhibitor racemate (CPA-I) D, L-benzylsuccinic acid. (n=5/group).
Controls are set at 100%. (E) and (F) mechanical hyperalgesia and cold allodynia in control and D, L-benzylsuccinic acid treated mice, respectively.
(n=6 animals in each group), m controls, X CPA-Inhibitor. Data are means 6 SEM, *P,0.05.
doi:10.1371/journal.pone.0019270.g005
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